BIND-014

DRUG3 trials

Sponsors

BIND Therapeutics

Conditions

CRPCCancerMetastatic CancerNon-small Cell Lung CancerProstate CancerSolid Tumors

Phase 1

A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

CompletedNCT01300533

BIND TherapeuticsCancer, Metastatic Cancer, Solid Tumors

Start: 2011-01-31End: 2016-02-29Updated: 2016-02-09

Phase 2

A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer

CompletedNCT01792479

BIND TherapeuticsNon-small Cell Lung Cancer

Start: 2013-04-30End: 2016-04-30Updated: 2016-04-15

A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer

CompletedNCT01812746

BIND TherapeuticsCRPC, Prostate Cancer

Start: 2013-04-30End: 2016-04-30Updated: 2016-04-15

Related Papers

Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer

JAMA Oncology2018-07-06239 citations

Abstract 1329: Intravenous delivery of Erlotinib-loaded PLA-PEG nanoparticles for treatment of GB

Cancer Research2016-07-15

A phase 2 study of BIND-014 (PSMA-targeted docetaxel nanoparticle) administered to patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2016-01-1033 citations